These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 8731322)

  • 1. [Lipid changes of fibrinogen and of platelet aggregation induced by etofibrate].
    Fonseca FA; Novazzi JP; Cendoroglo MS; Duarte M; Almeida Pinto LE; Rabelo LM; da Rocha Martinez TL
    Arq Bras Cardiol; 1996 Jan; 66(1):33-5. PubMed ID: 8731322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Etofibrate therapy and effect of added low-dose cholestyramine in patients with combined hyperlipidaemia.
    Krüger B
    Int J Clin Pharmacol Res; 1994; 14(5-6):177-83. PubMed ID: 7672874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Etofibrate decreases factor VII and fibrinogen levels in patients with polymetabolic syndrome.
    Jastrzebska M; Torbus-Lisiecka B; Pieczul-Mróz J; Chelstowski K; Kopciewicz J; Naruszewicz M
    Int J Clin Pharmacol Res; 1999; 19(1):19-25. PubMed ID: 10450539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Evaluation of efficacy and safety of etofibrate in primary hyperlipidemia. A multicenter study].
    dos Santos JE; Loures-Vale AA; Novazzi JP; Rabelo LM; Martinez TL
    Arq Bras Cardiol; 1996 Dec; 67(6):419-22. PubMed ID: 9246832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Etofibrate treatment alters low density lipoprotein susceptibility to lipid peroxidation.
    Wülfroth P; Richter CM; Burkard M; Huth K; Quack G
    Drugs Exp Clin Res; 1992; 18(11-12):469-74. PubMed ID: 1308472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Regression of hard exudates in diabetic background retinopathy in therapy with etofibrate antilipemic agent].
    Freyberger H; Schifferdecker E; Schatz H
    Med Klin (Munich); 1994 Nov; 89(11):594-7, 633. PubMed ID: 7815987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Changes in serum lipids, plasma fibrinogen and other haemostatic parameters induced by ciprofibrate action in hyperlipidemic patients with and without coronary artery disease].
    Espinosa RA; Rodríguez-Roa E; Nagy E; Mijares ME; Rodríguez-Larralde A; Gil A; Lundberg U; Carvajal Z; Castillo L; Arocha-Piñango CL
    Invest Clin; 2006 Mar; 47(1):35-48. PubMed ID: 16562643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of bezafibrate on lipids, lipoproteins, apolipoproteins and platelet aggregation in hypertriglyceridemic patients.
    Waysbort J; Schwartz S; Brunner D
    Arzneimittelforschung; 1994 Nov; 44(11):1217-22. PubMed ID: 7893284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy and safety of etofibrate in patients with non-proliferative diabetic retinopathy].
    Emmerich KH; Poritis N; Stelmane I; Klindzane M; Erbler H; Goldsteine J; Görtelmeyer R
    Klin Monbl Augenheilkd; 2009 Jul; 226(7):561-7. PubMed ID: 19644802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of Etofibrate (Lipo-Merz) on "in vitro" cellular immune response and on lipid parameters of men with myocardial infarction and with arteriosclerosis obliterans.
    Horváth M; Varsányl M; Jovanovich N; Romics L; Gerö S
    Allergol Immunopathol (Madr); 1990; 18(2):95-9. PubMed ID: 2371944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Etofibrate increases binding of low and high density lipoprotein to human platelets of patients with type II hyperlipoproteinemia.
    Virgolini I; Koller E; Li S; Yang Q; Banyai M; Rauscha F; Pidlich J; Pirker W; Sinzinger H
    Atherosclerosis; 1993 Sep; 102(2):217-26. PubMed ID: 8251008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of policosanol and pravastatin on lipid profile, platelet aggregation and endothelemia in older hypercholesterolemic patients.
    Castaño G; Más R; Arruzazabala ML; Noa M; Illnait J; Fernández JC; Molina V; Menéndez A
    Int J Clin Pharmacol Res; 1999; 19(4):105-16. PubMed ID: 10939028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of ciprofibrate on the endothelial dysfunction of patients with combined dyslipidemia].
    Kovács I; Tarján J; Császár A
    Orv Hetil; 2001 Apr; 142(15):775-9. PubMed ID: 11367862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effectiveness of etofibrate in arteriosclerosis obliterans. Pilot study in hyperlipidemic patients with arteriosclerosis obliterans].
    Dembińska-Kieć A; Kostka-Trabka E; Grodzińska L; Bieroń K; Kedzior A; Basista M; Zmuda A; Trabka E; Slawiński M; Czarnecka H
    Fortschr Med; 1989 Jul; 107(20):450-2. PubMed ID: 2767596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The effect of micronized fenofibrate on lipid parameters and fibrinogen in heterozygous familial hypercholesterolemia and familial combined hyperlipidemia].
    Ceska R; Sobra J; Kvasnicka J; Procházková R; Kvasilová M; Haas T
    Cas Lek Cesk; 1996 Jul; 135(13):413-6. PubMed ID: 8925538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ciprofibrate treatment decreases non-high density lipoprotein cholesterol and triglycerides and increases high density lipoprotein cholesterol in patients with Frederickson type IV dyslipidemia phenotype.
    Bermúdez-Pirela V; Souki A; Cano-Ponce C; Bermúdez-Arias F; Mengual-Moreno E; Leal-Gonzalez E; Lemus-Antepaz M; de Bravo MC; de Díaz AA; de Pirela NL; Cano-Peñaloza R; Puche-Medina G; Arraiz N; Reyna-Villazmil N; Contreras F; Israili ZH; Valasco M
    Am J Ther; 2007; 14(2):213-20. PubMed ID: 17414592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Ciprofibrate on platelet aggregation and fibrinolysis in patients with hypercholesterolaemia.
    Simpson IA; Lorimer AR; Walker ID; Davidson JF
    Thromb Haemost; 1985 Aug; 54(2):442-4. PubMed ID: 4082082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Confirmation of efficacy of etofibrate against peripheral atherosclerosis in non-human primates which model human lesion types I-VII.
    Fincham JE; Quack G; Wülfroth P; Benadé AJ
    Arzneimittelforschung; 1996 May; 46(5):519-25. PubMed ID: 8737639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do platelet apoptosis, activation, aggregation, lipid peroxidation and platelet-leukocyte aggregate formation occur simultaneously in hyperlipidemia?
    Sener A; Ozsavci D; Oba R; Demirel GY; Uras F; Yardimci KT
    Clin Biochem; 2005 Dec; 38(12):1081-7. PubMed ID: 16253220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical research into the hypolipemic and platelet antiaggregant activity of plafibride, Carried out in double-blind conditions and in comparison with clofibrate.
    Palmieri B; Gasparini Casari M; DiBlasio P; Zirilli E
    Arzneimittelforschung; 1981; 31(10a):1863-6. PubMed ID: 7032534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.